Aliases & Classifications for Eating Disorder

MalaCards integrated aliases for Eating Disorder:

Name: Eating Disorder 12 14
Eating Disorders 36 51 40 69

Classifications:



External Ids:

Disease Ontology 12 DOID:8670
ICD10 32 F50 F50.9
ICD9CM 34 307.50
NCIt 46 C89332
KEGG 36 H01703
UMLS 69 C0013473

Summaries for Eating Disorder

MedlinePlus : 40 Eating disorders are serious behavior problems. They can include severe overeating or not consuming enough food to stay healthy. They also involve extreme concern about your shape or weight. Types of eating disorders include Anorexia nervosa, in which you become too thin, but you don't eat enough because you think you are fat Bulimia nervosa, which involves periods of overeating followed by purging, sometimes through self-induced vomiting or using laxatives Binge-eating, which is out-of-control eating Women are more likely than men to have eating disorders. They usually start in the teenage years and often occur along with depression, anxiety disorders, and substance abuse. Eating disorders can lead to heart and kidney problems and even death. Getting help early is important. Treatment involves monitoring, talk therapy, nutritional counseling, and sometimes medicines. NIH: National Institute of Mental Health

MalaCards based summary : Eating Disorder, also known as eating disorders, is related to bulimia nervosa 1 and borderline personality disorder, and has symptoms including symptoms concerning nutrition, metabolism, and development, adipsia and decrease in appetite. An important gene associated with Eating Disorder is GHRL (Ghrelin And Obestatin Prepropeptide), and among its related pathways/superpathways are Adipocytokine signaling pathway and cAMP signaling pathway. The drugs Dopamine and Topiramate have been mentioned in the context of this disorder. Affiliated tissues include bone, brain and heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A specific developmental disorder that is characterized by abnormal eating habits that may involve either insufficient or excessive food intake to the detriment of an individual's physical and emotional health.

Wikipedia : 72 An eating disorder is a mental disorder defined by abnormal eating habits that negatively affect a... more...

Related Diseases for Eating Disorder

Diseases related to Eating Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 195)
# Related Disease Score Top Affiliating Genes
1 bulimia nervosa 1 31.7 BDNF CCK COMT GHRL LEP MC4R
2 borderline personality disorder 31.6 BDNF COMT HTR2C SLC6A4
3 autism spectrum disorder 30.5 BDNF COMT DRD2 OXTR SLC6A3 SLC6A4
4 dyspepsia 30.1 CCK GHRL SLC6A4
5 pathological gambling 30.1 DRD2 SLC6A3 SLC6A4
6 alexithymia 30.1 COMT DRD2 OXTR SLC6A4
7 social phobia 30.0 CCK DRD2 SLC6A4
8 alcohol abuse 29.9 BDNF CNR1 DRD2 SLC6A4
9 chronic pain 29.8 CNR1 COMT
10 generalized anxiety disorder 29.8 BDNF DRD2 SLC6A4
11 personality disorder 29.6 BDNF COMT DRD2 HTR2C SLC6A3 SLC6A4
12 celiac disease 1 29.4 CCK GHRL PYY
13 restless legs syndrome 29.4 COMT DRD2 SLC6A3
14 bulimia nervosa 2 29.4 ADIPOQ BDNF CCK COMT GHRL LEP
15 narcolepsy 29.3 COMT DRD2 GHRL LEP SLC6A3
16 obsessive-compulsive disorder 29.3 BDNF COMT DRD2 HTR2C SLC6A3 SLC6A4
17 anxiety 29.1 BDNF CCK CNR1 COMT HTR2C NPY
18 substance abuse 29.1 BDNF COMT DRD2 NPY SLC6A3 SLC6A4
19 bipolar disorder 29.1 BDNF COMT DRD2 HTR2C SLC6A3 SLC6A4
20 autism 29.0 BDNF COMT DRD2 OXTR SLC6A4
21 attention deficit-hyperactivity disorder 28.9 BDNF COMT DRD2 HTR2C NPY SLC6A3
22 panic disorder 28.9 BDNF CCK COMT HTR2C POMC SLC6A4
23 substance dependence 28.8 BDNF CNR1 DRD2 POMC SLC6A3 SLC6A4
24 mood disorder 28.6 BDNF COMT DRD2 HTR2C NPY POMC
25 morbid obesity 28.2 ADIPOQ CCK GHRL LEP LEPR MC4R
26 schizophrenia 27.9 BDNF CCK CNR1 COMT DRD2 HTR2C
27 major depressive disorder 27.3 BDNF COMT DRD2 HTR2C NPY OXTR
28 body mass index quantitative trait locus 11 27.1 ADIPOQ CCK CNR1 DRD2 GHRL HTR2C
29 disease of mental health 26.7 BDNF CCK CNR1 COMT DRD2 HTR2C
30 rumination disorder 11.5
31 extrapontine myelinolysis 10.9
32 anorexia nervosa 1 10.8
33 wernicke-korsakoff syndrome 10.8
34 osteoporosis, juvenile 10.6
35 pica disease 10.6
36 telogen effluvium 10.6
37 central pontine myelinolysis 10.6
38 brittle diabetes 10.6
39 mbd25-related intellectual disability 10.6
40 cerebral beriberi 10.6
41 korsakoff's amnesic syndrome 10.6
42 body mass index quantitative trait locus 9 10.6
43 body mass index quantitative trait locus 8 10.6
44 body mass index quantitative trait locus 7 10.6
45 body mass index quantitative trait locus 12 10.6
46 body mass index quantitative trait locus 14 10.6
47 body mass index quantitative trait locus 18 10.6
48 body mass index quantitative trait locus 4 10.6
49 body mass index quantitative trait locus 10 10.6
50 alcohol use disorder 10.4 DRD2 SLC6A4

Comorbidity relations with Eating Disorder via Phenotypic Disease Network (PDN):


Major Depressive Disorder

Graphical network of the top 20 diseases related to Eating Disorder:



Diseases related to Eating Disorder

Symptoms & Phenotypes for Eating Disorder

UMLS symptoms related to Eating Disorder:


symptoms concerning nutrition, metabolism, and development, adipsia, decrease in appetite

MGI Mouse Phenotypes related to Eating Disorder:

43 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.5 SLC6A4 BDNF COMT DRD2 CCK ADIPOQ
2 homeostasis/metabolism MP:0005376 10.43 SLC6A4 ADIPOQ CNR1 BDNF COMT DRD2
3 growth/size/body region MP:0005378 10.38 SLC6A4 ADIPOQ CNR1 BDNF DRD2 LEPR
4 endocrine/exocrine gland MP:0005379 10.33 SLC6A4 ADIPOQ BDNF COMT DRD2 CCK
5 adipose tissue MP:0005375 10.32 CNR1 DRD2 ADIPOQ LEPR GHRL HTR2C
6 nervous system MP:0003631 10.31 SLC6A4 CNR1 BDNF COMT DRD2 CCK
7 integument MP:0010771 10.25 SLC6A4 ADIPOQ CNR1 BDNF DRD2 LEPR
8 normal MP:0002873 10.11 SLC6A4 CNR1 BDNF GHRL LEPR DRD2
9 digestive/alimentary MP:0005381 10.1 CNR1 BDNF LEP DRD2 GHRL LEPR
10 muscle MP:0005369 10.08 SLC6A3 SLC6A4 ADIPOQ DRD2 LEP LEPR
11 liver/biliary system MP:0005370 10.04 ADIPOQ LEP DRD2 LEPR MC4R POMC
12 no phenotypic analysis MP:0003012 10.01 CNR1 BDNF CCK LEPR DRD2 OXTR
13 neoplasm MP:0002006 9.93 ADIPOQ LEP DRD2 LEPR MC4R POMC
14 renal/urinary system MP:0005367 9.92 ADIPOQ COMT CCK LEP LEPR DRD2
15 reproductive system MP:0005389 9.91 SLC6A3 CNR1 COMT BDNF DRD2 LEP
16 respiratory system MP:0005388 9.7 ADIPOQ COMT BDNF LEP DRD2 LEPR
17 skeleton MP:0005390 9.61 SLC6A3 ADIPOQ CNR1 DRD2 LEP LEPR
18 taste/olfaction MP:0005394 8.92 SLC6A3 CNR1 BDNF DRD2

Drugs & Therapeutics for Eating Disorder

Drugs for Eating Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 272)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
2
Topiramate Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 97240-79-4 5284627
3
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
4
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
5
Ethanol Approved Phase 4,Phase 2,Phase 3 64-17-5 702
6
Norepinephrine Approved Phase 4 51-41-2 439260
7
Baclofen Approved Phase 4 1134-47-0 2284
8
Zinc Approved, Investigational Phase 4,Phase 1,Phase 2 7440-66-6 32051 23994
9
Memantine Approved, Investigational Phase 4 19982-08-2 4054
10
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
11
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2 132539-06-1 4585
12
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
13
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2 300-62-9 3007 5826
14
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 16590-41-3 5360515
15
Liraglutide Approved Phase 4,Phase 3 204656-20-2 44147092
16
Phentermine Approved, Illicit Phase 4,Phase 2,Phase 1 122-09-8 4771
17
Dextroamphetamine Approved, Illicit Phase 4,Phase 2 51-64-9 5826
18
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
19
Cyproheptadine Approved Phase 4 129-03-3 2913
20 Zinc sulfate Approved, Investigational Phase 4 7733-02-0
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
22
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
23 Raclopride Investigational Phase 4 84225-95-6
24
Serotonin Phase 4,Phase 3,Phase 2 50-67-9 5202
25 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
26 Micronutrients Phase 4,Phase 1,Phase 2
27 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1
28 Serotonin Agents Phase 4,Phase 3,Phase 2
29 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2
30 Narcotic Antagonists Phase 4,Phase 2,Phase 3
31 Narcotics Phase 4,Phase 2,Phase 3
32 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Trace Elements Phase 4,Phase 1,Phase 2
35 Tranquilizing Agents Phase 4,Phase 3,Phase 2
36 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2
37 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2,Phase 3
38 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
39 Vitamin B Complex Phase 4
40 Vitamins Phase 4,Phase 3
41 Dopamine Agents Phase 4,Phase 3,Phase 2
42 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
43 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2
44 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Antidepressive Agents Phase 4,Phase 3,Phase 2
46 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Phase 3
47 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Anti-Obesity Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
49 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
50 Antipsychotic Agents Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 563)

# Name Status NCT ID Phase Drugs
1 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
2 Folic Acid Supplementation in Eating Disorder Completed NCT01493674 Phase 4
3 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4 [11C]raclopride;[11C]DASB;amphetamine
4 An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder Completed NCT00330655 Phase 4 memantine
5 Atomoxetine in the Treatment of Binge Eating Disorder Completed NCT00327834 Phase 4 atomoxetine
6 Effectiveness of Binge Eating Disorder Treatments Completed NCT00060762 Phase 4
7 Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression Completed NCT00607789 Phase 4 Duloxetine;Placebo
8 Antidepressant Safety in Kids Study Completed NCT00395213 Phase 4 Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications
9 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
10 Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa Completed NCT00685334 Phase 4 Olanzapine;Aripiprazole
11 Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa Completed NCT00288574 Phase 4 Fluoxetine;Placebo
12 Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm Completed NCT02060084 Phase 4 a control group;a probiotic-supplemented group
13 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4 Risperidone;Placebo
14 Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese Completed NCT01739049 Phase 4 Liraglutide
15 Olanzapine in the Treatment of Anorexia Nervosa Completed NCT00592930 Phase 4 olanzapine;placebo
16 The Effects of Body Contouring: Abdominoplasty and Liposuction Completed NCT02151799 Phase 4
17 Baclofen for Rumination Completed NCT03113396 Phase 4 Baclofen;Placebo oral capsule
18 Treatment of Binge Eating in Obese Patients in Primary Care Completed NCT00537810 Phase 4 Sibutramine;Placebo
19 Impact of Behavioral Feeding Intervention on Parent-Child Attachment in Young Children Completed NCT02187952 Phase 4
20 Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons Completed NCT00516919 Phase 4 Xenical + behavioral intervention
21 Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults Completed NCT02706067 Phase 4 Orlistat
22 Near Infrared Spectroscopy (NIRS) and Superior Mesenteric Artery (SMA) Doppler Patterns as Predictor of Feeding Tolerance in Very Low Birth Weight (VLBW) IntraUterine Growth Restricted (IUGR) and NON IUGR Infants Completed NCT01341236 Phase 4
23 Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF. Recruiting NCT02359513 Phase 4 Antidepressants;Positron Emission Tomography (PET)
24 Lifestyle Modification and Liraglutide Active, not recruiting NCT02911818 Phase 4 Liraglutide 3.0mg;Placebo Oral Tablet;Phentermine 15 MG
25 Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders Not yet recruiting NCT02568007 Phase 4 Cyproheptadine
26 Effect of Zinc Supplementation on Appetite and Growth in Primary Malnourished Children Not yet recruiting NCT03098810 Phase 4 Zinc sulphate
27 Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder Withdrawn NCT01372670 Phase 4 Hydroxyzine;hydroxyzine HCL
28 Topiramate Augmentation in Bulimia Nervosa Partial Responders Withdrawn NCT00988481 Phase 4 Topiramate
29 Clinical Trial on Binge Eating Disorder, Treatment With Naloxone Spray Unknown status NCT01567670 Phase 2, Phase 3 Naloxone;naloxone placebo
30 Improving Patient Outcome in Group Therapy for Eating Disorders Unknown status NCT01693237 Phase 2, Phase 3
31 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
32 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
33 ARIpiprazole in Anorexia NErvosa Unknown status NCT01082848 Phase 3 aripiprazole;placebo
34 Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity Completed NCT00277641 Phase 3 Lamotrigine;placebo
35 Dasotraline Binge Eating Disorder Study Completed NCT02564588 Phase 2, Phase 3 Dasotraline;Placebo
36 Open Label Extension in Adults With Binge Eating Disorder (BED) Completed NCT01657019 Phase 3 Lisdexamfetamine dimesylate
37 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718483 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
38 Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder Completed NCT01090713 Phase 3 lisdexamfetamine;Placebo control
39 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718509 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
40 Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity Completed NCT00221442 Phase 3 Zonegran;sugar pill
41 A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity Completed NCT00210808 Phase 2, Phase 3 topiramate
42 Meditation-Based Treatment for Binge Eating Disorder Completed NCT00032760 Phase 2, Phase 3
43 An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder. Completed NCT00307619 Phase 3 topiramate
44 Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT02009163 Phase 3 Lisdexamfetamine dimesylate
45 A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder Completed NCT00402584 Phase 3 sibutramine
46 Sodium Oxybate in the Treatment of Binge Eating Disorder Completed NCT00514995 Phase 2, Phase 3 Sodium Oxybate
47 Acamprosate in the Treatment of Binge-Eating Disorder Completed NCT00511940 Phase 2, Phase 3 acamprosate
48 Armodafinil in Binge Eating Disorder (BED) Completed NCT01010789 Phase 3 Armodafinil;Armodafinil;Matching placebo
49 Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients Completed NCT00481975 Phase 3 rimonabant (SR141716)
50 Craving, Binge Eating and Obesity Completed NCT00414167 Phase 2, Phase 3 bupropion

Search NIH Clinical Center for Eating Disorder

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Eating Disorder

Anatomical Context for Eating Disorder

MalaCards organs/tissues related to Eating Disorder:

38
Bone, Brain, Heart, Testes, Kidney, Liver, Ovary

Publications for Eating Disorder

Articles related to Eating Disorder:

(show top 50) (show all 986)
# Title Authors Year
1
Inducing negative affect using film clips with general and eating disorder-related content. ( 29423687 )
2018
2
Beyond the Binary: Differences in Eating Disorder Prevalence by Gender Identity in a Transgender Sample. ( 29359198 )
2018
3
Improving access to eating disorder services. ( 29378681 )
2018
4
The Contribution of Social Media to Body Dissatisfaction, Eating Disorder Symptoms, and Anabolic Steroid Use Among Sexual Minority Men. ( 29363993 )
2018
5
A content analysis of an online pro-eating disorder community on Reddit. ( 29414146 )
2018
6
Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature. ( 29407005 )
2018
7
Living with someone with an eating disorder: factors affecting the caregivers' burden. ( 29368292 )
2018
8
Media Smart-Targeted: Diagnostic outcomes from a two-country pragmatic online eating disorder risk reduction trial for young adults. ( 29377203 )
2018
9
Food specific inhibitory control under negative mood in binge-eating disorder: Evidence from a multimethod approach. ( 29341203 )
2018
10
Hypomagnesemia in a Patient With an Eating Disorder. ( 29389386 )
2018
11
Eating disorders in children: is avoidant-restrictive food intake disorder a feeding disorder or an eating disorder and what are the implications for treatment? ( 29399331 )
2018
12
Ghrelin concentration as an indicator of eating-disorder risk in obese women. ( 29395813 )
2018
13
Affective predictors of the severity and change in eating psychopathology in residential eating disorder treatment: The role of social anxiety. ( 29384466 )
2018
14
Meta-analysis of the effects of cognitive-behavioral therapy on the core eating disorder maintaining mechanisms: implications for mechanisms of therapeutic change. ( 29378481 )
2018
15
Network analysis: An innovative framework for understanding eating disorder psychopathology. ( 29451959 )
2018
16
Binge eating disorder and depressive symptoms among females of child-bearing age: the Korea Nurses' Health Study. ( 29343226 )
2018
17
Variation in reproductive outcomes of women with histories of bulimia nervosa, anorexia nervosa, or eating disorder not otherwise specified relative to the general population and closest-aged sisters. ( 29331083 )
2018
18
Economic evaluation of cognitive behavioral therapy and Internet-based guided self-help for binge-eating disorder. ( 29345848 )
2018
19
A narrative review of binge eating disorder in adolescence: prevalence, impact, and psychological treatment strategies. ( 29379325 )
2018
20
The impact of early shame memories in Binge Eating Disorder: The mediator effect of current body image shame and cognitive fusion. ( 28890226 )
2017
21
Relationship between Risk Behavior for Eating Disorders and Dental Caries and Dental Erosion. ( 29423431 )
2017
22
Age effects in eating disorder baseline risk factors and prevention intervention effects. ( 28861902 )
2017
23
Associations between eating disorder related symptoms and participants' utilization of an individualized Internet-based prevention and early intervention program. ( 28921689 )
2017
24
Predicting intolerance of uncertainty in individuals with eating disorder symptoms. ( 28883918 )
2017
25
Fat mass and obesity-associated gene (FTO) is associated to eating disorders susceptibility and moderates the expression of psychopathological traits. ( 28282466 )
2017
26
Psychiatric comorbidity and maternal distress among adolescent eating disorder patients: A comparison with substance use disorder patients. ( 28039823 )
2017
27
Predictors of comorbid eating disorders and association with other obsessive-compulsive spectrum disorders in trichotillomania. ( 28667830 )
2017
28
Explicit and Implicit Approach vs. Avoidance Tendencies towards High vs. Low Calorie Food Cues in Patients with Obesity and Active Binge Eating Disorder. ( 28953225 )
2017
29
Treating the binge or the (fat) body? Representations of fatness in a gold standard psychological treatment manual for binge eating disorder. ( 28064539 )
2017
30
Molecular bases of anorexia nervosa, bulimia nervosa and binge eating disorder: shedding light on the darkness. ( 28762842 )
2017
31
Experiential avoidance, eating expectancies, and binge eating: A preliminary test of an adaption of the Acquired Preparedness Model of eating disorder risk. ( 28947185 )
2017
32
Attention-deficit/hyperactivity disorder symptoms and psychological comorbidity in eating disorder patients. ( 28534123 )
2017
33
A systematic review and narrative synthesis of interventions for uncomplicated obesity: weight loss, well-being and impact on eating disorder. ( 28889945 )
2017
34
A Randomised Controlled Comparison of Second-Level Treatment Approaches for Treatment-Resistant Adults with Bulimia Nervosa and Binge Eating Disorder: Assessing the Benefits of Virtual Reality Cue Exposure Therapy. ( 28804985 )
2017
35
Fifty years of anorexia nervosa and other eating disorders in the Australian & New Zealand Journal of Psychiatry. ( 28521537 )
2017
36
Social phobia, depression and eating disorders during middle adolescence: longitudinal associations and treatment seeking. ( 28868945 )
2017
37
Prevalence and correlates of binge eating disorder related features in the community. ( 27899295 )
2017
38
New Horizons in Measurement: a Review of Novel and Innovative Approaches to Eating-Disorder Assessment. ( 28891029 )
2017
39
Rumination in Patients with Binge-Eating Disorder and Obesity: Associations with Eating-Disorder Psychopathology and Weight-bias Internalization. ( 28078784 )
2017
40
Visual Attention to Ambiguous Emotional Faces in Eating Disorders: Role of Alexithymia. ( 28762613 )
2017
41
Autonomy support and autonomous motivation in the outpatient treatment of adults with an eating disorder. ( 28842966 )
2017
42
Addison's Disease and Possible Cannabis Withdrawal Syndrome Presenting as an Eating Disorder in a Thirty-Year-Old Female. ( 28348901 )
2017
43
Correlates of weight-related quality of life among individuals with binge eating disorder before and after cognitive behavioral therapy. ( 28843136 )
2017
44
Pornography use in sexual minority males: Associations with body dissatisfaction, eating disorder symptoms, thoughts about using anabolic steroids and quality of life. ( 28891676 )
2017
45
Association Between Oxytocin Receptor Genotype, Maternal Care, and Eating Disorder Behaviours in a Community Sample of Women. ( 27862641 )
2017
46
Evidence for ERP biomarkers of eating disorder symptoms in women. ( 28057515 )
2017
47
Female athlete experiences of seeking and receiving treatment for an eating disorder. ( 28051927 )
2017
48
Increasing body image flexibility in a residential eating disorder facility: Correlates with symptom improvement. ( 28929944 )
2017
49
Potential psychological & neural mechanisms in binge eating disorder: Implications for treatment. ( 29329692 )
2017
50
Eating Disorder Examination Questionnaire (EDE-Q) and Clinical Impairment Assessment (CIA): clinical norms and functional impairment in male and female adults with eating disorders. ( 28084126 )
2017

Variations for Eating Disorder

Expression for Eating Disorder

Search GEO for disease gene expression data for Eating Disorder.

Pathways for Eating Disorder

Pathways related to Eating Disorder according to KEGG:

36
# Name Kegg Source Accession
1 Adipocytokine signaling pathway hsa04920
2 cAMP signaling pathway hsa04024

Pathways related to Eating Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 CCK CNR1 DRD2 GHRL HTR2C LEP
2
Show member pathways
12.67 CCK CNR1 DRD2 GHRL HTR2C LEP
3 12.33 CNR1 COMT NPY POMC
5
Show member pathways
11.86 BDNF DRD2 GHRL NPY OXTR
6
Show member pathways
11.72 BDNF DRD2 SLC6A3
7 11.19 ADIPOQ LEP LEPR NPY POMC
8
Show member pathways
11.02 LEP LEPR POMC
9
Show member pathways
10.91 COMT SLC6A3 SLC6A4
10 10.69 MC4R POMC
11 10.55 CCK CNR1

GO Terms for Eating Disorder

Cellular components related to Eating Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 ADIPOQ CCK GHRL LEP NPY POMC
2 extracellular region GO:0005576 9.61 ADIPOQ BDNF CCK GHRL LEP LEPR
3 axon GO:0030424 9.1 CCK CNR1 COMT DRD2 GHRL SLC6A3

Biological processes related to Eating Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.96 CCK CNR1 DRD2 GHRL HTR2C MC4R
2 response to hypoxia GO:0001666 9.9 ADIPOQ DRD2 LEP SLC6A4
3 response to organic cyclic compound GO:0014070 9.89 COMT OXTR SLC6A3
4 neuropeptide signaling pathway GO:0007218 9.89 NPY POMC PYY
5 response to estradiol GO:0032355 9.89 LEP OXTR SLC6A4
6 female pregnancy GO:0007565 9.87 COMT LEP OXTR
7 response to drug GO:0042493 9.87 ADIPOQ COMT DRD2 HTR2C OXTR SLC6A3
8 locomotory behavior GO:0007626 9.86 DRD2 HTR2C SLC6A3
9 circadian rhythm GO:0007623 9.86 ADIPOQ LEP SLC6A4
10 memory GO:0007613 9.83 CNR1 OXTR SLC6A4
11 regulation of blood pressure GO:0008217 9.83 LEP NPY POMC
12 response to ethanol GO:0045471 9.83 ADIPOQ CNR1 DRD2 LEP SLC6A3
13 positive regulation of synapse assembly GO:0051965 9.82 BDNF GHRL OXTR
14 glucose metabolic process GO:0006006 9.81 ADIPOQ GHRL LEP
15 response to nutrient GO:0007584 9.81 ADIPOQ CNR1 LEP SLC6A4
16 response to nutrient levels GO:0031667 9.8 ADIPOQ GHRL LEP
17 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.78 CNR1 DRD2 MC4R
18 glucose homeostasis GO:0042593 9.77 ADIPOQ CNR1 LEP LEPR POMC
19 response to nicotine GO:0035094 9.76 CNR1 DRD2 SLC6A3
20 regulation of receptor activity GO:0010469 9.76 ADIPOQ BDNF CCK GHRL LEP NPY
21 positive regulation of multicellular organism growth GO:0040018 9.74 DRD2 GHRL SLC6A3
22 negative regulation of blood pressure GO:0045776 9.73 ADIPOQ CNR1 DRD2
23 eating behavior GO:0042755 9.72 CCK LEP OXTR
24 response to iron ion GO:0010039 9.71 DRD2 SLC6A3
25 dopamine metabolic process GO:0042417 9.71 COMT DRD2
26 neurotransmitter biosynthetic process GO:0042136 9.71 SLC6A3 SLC6A4
27 response to cocaine GO:0042220 9.71 CNR1 DRD2 OXTR SLC6A3
28 ammonium transmembrane transport GO:0072488 9.7 SLC6A3 SLC6A4
29 prepulse inhibition GO:0060134 9.7 DRD2 SLC6A3
30 negative regulation of gluconeogenesis GO:0045721 9.7 ADIPOQ LEPR
31 regulation of synaptic transmission, GABAergic GO:0032228 9.7 CNR1 DRD2
32 positive regulation of blood pressure GO:0045777 9.7 ADIPOQ CNR1 OXTR
33 central nervous system neuron development GO:0021954 9.69 LEP NPY
34 behavior GO:0007610 9.68 HTR2C NPY
35 sexual reproduction GO:0019953 9.68 LEP LEPR
36 leptin-mediated signaling pathway GO:0033210 9.67 LEP LEPR
37 positive regulation of growth hormone secretion GO:0060124 9.67 DRD2 GHRL
38 adenohypophysis development GO:0021984 9.67 DRD2 SLC6A3
39 energy reserve metabolic process GO:0006112 9.67 LEP LEPR MC4R
40 negative regulation of appetite GO:0032099 9.66 CCK LEP
41 monoamine transport GO:0015844 9.66 SLC6A3 SLC6A4
42 dopamine catabolic process GO:0042420 9.65 COMT SLC6A3
43 regulation of feeding behavior GO:0060259 9.65 CNR1 LEPR MC4R
44 regulation of bone remodeling GO:0046850 9.63 LEP LEPR
45 adult feeding behavior GO:0008343 9.63 GHRL LEP NPY
46 dopamine uptake involved in synaptic transmission GO:0051583 9.62 SLC6A3 SLC6A4
47 sperm ejaculation GO:0042713 9.62 OXTR SLC6A4
48 regulation of metabolic process GO:0019222 9.61 LEP MC4R
49 positive regulation of appetite GO:0032100 9.59 GHRL NPY
50 negative regulation of dopamine secretion GO:0033602 9.58 CNR1 DRD2

Molecular functions related to Eating Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.93 CNR1 DRD2 HTR2C MC4R NPY OXTR
2 signal transducer activity GO:0004871 9.8 CNR1 DRD2 HTR2C MC4R OXTR
3 receptor binding GO:0005102 9.8 ADIPOQ DRD2 LEP NPY POMC SLC6A3
4 drug binding GO:0008144 9.56 CNR1 DRD2 HTR2C SLC6A3
5 neurotransmitter:sodium symporter activity GO:0005328 9.49 SLC6A3 SLC6A4
6 dopamine binding GO:0035240 9.48 DRD2 SLC6A3
7 G-protein coupled receptor binding GO:0001664 9.46 GHRL NPY POMC PYY
8 monoamine transmembrane transporter activity GO:0008504 9.43 SLC6A3 SLC6A4
9 dopamine:sodium symporter activity GO:0005330 9.37 SLC6A3 SLC6A4
10 neuropeptide hormone activity GO:0005184 9.26 CCK NPY POMC PYY
11 hormone activity GO:0005179 9.17 ADIPOQ CCK GHRL LEP NPY POMC

Sources for Eating Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....